These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 6363093)
21. Mechanisms of local immunoresistance in glioma. Albesiano E; Han JE; Lim M Neurosurg Clin N Am; 2010 Jan; 21(1):17-29. PubMed ID: 19944963 [TBL] [Abstract][Full Text] [Related]
22. Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. Yang L; Ng KY; Lillehei KO Cancer Control; 2003; 10(2):138-47. PubMed ID: 12712008 [TBL] [Abstract][Full Text] [Related]
23. [Immunotherapy for malignant gliomas (author's transl)]. Ishizawa A Neurol Med Chir (Tokyo); 1981 Feb; 21(2):179-91. PubMed ID: 6164941 [No Abstract] [Full Text] [Related]
24. A preliminary study utilizing viable HLA mismatched cultured glioma cells as adjuvant therapy for patients with malignant gliomas. Bullard DE; Thomas DG; Darling JL; Wikstrand CJ; Diengdoh JV; Barnard RO; Bodmer JG; Bigner DD Br J Cancer; 1985 Feb; 51(2):283-9. PubMed ID: 3966985 [No Abstract] [Full Text] [Related]
25. [Immunology and immunotherapy of cerebral tumors. Current status]. Trouillas P Rev Neurol (Paris); 1973 Jan; 128(1):23-38. PubMed ID: 4367367 [No Abstract] [Full Text] [Related]
27. Cell- and peptide-based immunotherapeutic approaches for glioma. Yamanaka R Trends Mol Med; 2008 May; 14(5):228-35. PubMed ID: 18403264 [TBL] [Abstract][Full Text] [Related]
28. In situ dendritic cell vaccination for the treatment of glioma and literature review. Li M; Han S; Shi X Tumour Biol; 2016 Feb; 37(2):1797-801. PubMed ID: 26318301 [TBL] [Abstract][Full Text] [Related]
29. Recent advances in the role of toll-like receptors and TLR agonists in immunotherapy for human glioma. Deng S; Zhu S; Qiao Y; Liu YJ; Chen W; Zhao G; Chen J Protein Cell; 2014 Dec; 5(12):899-911. PubMed ID: 25411122 [TBL] [Abstract][Full Text] [Related]
31. Harnessing the immune system against human glioma. Dhodapkar KM; Banerjee D; Steinman RM Ann N Y Acad Sci; 2005 Dec; 1062():13-21. PubMed ID: 16461784 [TBL] [Abstract][Full Text] [Related]
32. Limitations of the C6/Wistar rat intracerebral glioma model: implications for evaluating immunotherapy. Parsa AT; Chakrabarti I; Hurley PT; Chi JH; Hall JS; Kaiser MG; Bruce JN Neurosurgery; 2000 Oct; 47(4):993-9; discussion 999-1000. PubMed ID: 11014444 [TBL] [Abstract][Full Text] [Related]
33. Monitoring immune responses after glioma vaccine immunotherapy. Jian B; Yang I; Parsa AT Neurosurg Clin N Am; 2010 Jan; 21(1):195-9. PubMed ID: 19944978 [TBL] [Abstract][Full Text] [Related]
34. [A role of brain in cell-mediated immunity and non-specific immunotherapy of brain tumors (author's transl)]. Kurisaka M; Tsubokawa T; Moriyasu N Neurol Med Chir (Tokyo); 1976 Jul; 16(4 pt 2):349-56. PubMed ID: 62315 [No Abstract] [Full Text] [Related]
35. Immunotherapy of brain tumors--is there a future? Mahaley MS Clin Neurosurg; 1978; 25():382-7. PubMed ID: 710003 [No Abstract] [Full Text] [Related]
36. Immunology of central nervous system tumors. de Micco C J Neuroimmunol; 1989 Dec; 25(2-3):93-108. PubMed ID: 2685042 [TBL] [Abstract][Full Text] [Related]
37. [Immunology of brain tumors: immunological situation of the brain]. Tanaka R; Sobue H No To Shinkei; 1983 May; 35(5):451-9. PubMed ID: 6354218 [No Abstract] [Full Text] [Related]
38. Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. Everson RG; Graner MW; Gromeier M; Vredenburgh JJ; Desjardins A; Reardon DA; Friedman HS; Friedman AH; Bigner DD; Sampson JH Expert Rev Anticancer Ther; 2008 May; 8(5):717-32. PubMed ID: 18471045 [TBL] [Abstract][Full Text] [Related]
39. [Virally mediated immunotherapy as a component of combined treatment in malignant cerebral glioma]. Kartashev AV; Vinogradov VM; Pozdniakov AV; Kiseleva LN; Iagunov AS Vopr Onkol; 2010; 56(3):278-82. PubMed ID: 20804048 [No Abstract] [Full Text] [Related]